WebNov 25, 2024 · Cyclophosphamide (CY) is an alkylating agent used widely to treat cancer and autoimmune diseases. Hyponatremia is a common adverse effect of high-dose and moderate-dose of intravenous CY, but is rare in patients treated with low-dose … Webcyclophosphamide should be administered in the morning. 2.1 Dosing for Malignant Diseases Adults and Pediatric Patients . Intravenous When used as the only oncolytic …
FAQ: Cyclophosphamide Patient Education UCSF Health
WebMar 6, 2024 · As high-dose intravenous cyclophosphamide is given with a fluid load to prevent hemorrhagic cystitis, SIADH in such patients is a particular problem, leading to potentially fatal hyponatremia. SSRIs … WebCyclophosphamide might either directly induce SIADH143–145 or stimulate ADH through cyclophosphamide-induced nausea.146,147 Hyponatremia typically occurs with high dose IV cyclophosphamide but has also been reported after oral cyclophosphamide or low-dose IV cyclophosphamide. chanson vulve
Cyclophosphamide-induced symptomatic hyponatraemia
WebCyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression … WebCyclophosphamide (Cytoxan; Cy) is an alkylating agent with cytotoxic and immunosuppressive activities. The parent compound is inactive in vitro and exerts its biologic activity through metabolites, mainly phosphoramide mustard generated by hepatic microsomal enzymes. WebMar 1, 1977 · Hyponatremia and hypochloremia from SIADH have been described with two cytotoxic agents: vincristine 26,47,82,94,125,129 and cyclophosphamide. 29 Hyponatremia associated with vincristine therapy has been seen in childhood leukemia 47,94,125,129 and in acute granulocytic leukemia in adults. 26,82 Fluid restriction or … chanson ykons